At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Scientists at the forum warned of an increasingly volatile health landscape
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Subscribe To Our Newsletter & Stay Updated
